EUVIMEDEUVIMED entdecken
Crossref

Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells

Gal Yagel, Dana Rimini, Michelle von Locquenghien, Roberto Avellino, Oren Barboy, Paulina Chalan, Gaya Granot, Ken Xie, Shir Shlomi-Loubaton, Fadi Sheban, Kfir Mazuz, Eyal David und 2 weitere

Cancer Cell · 2026-03 · 44 (3) · 519-533.e10

DOI: 10.1016/j.ccell.2025.11.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2026-03. Verfasst von Gal Yagel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel. Hauptthemen laut MEDLINE: Receptors, Immunologic, Membrane Glycoproteins, Immunotherapy, Adoptive, Tumor-Associated Macrophages. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 95 Literaturangaben. Gefördert von: Elsie & Marvin Dekelboum Family Foundation Rockville Inc, Israel Cancer Research Fund, Ministero della transizione ecologica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell therapy has shown remarkable success in hematologic malignancies and autoimmune diseases but remains limited in solid tumors due to antigen heterogeneity, escape, and an immunosuppressive tumor microenvironment (TME) dominated by tumor-associated macrophages (TAMs). We developed a macrophage-directed CAR T strategy targeting TREM2+ immunosuppressive TAMs, achieving potent in vitro activity and robust antitumor efficacy in vivo. To enhance intratumoral activity, we incorporated synthetic CAR-responsive biosensors containing NFAT, IRF, and AP1 motifs that enable localized IL-12 secretion upon activation. In an immunocompetent human TREM2 transgenic murine model, IL-12-armored hTREM2 CAR T cells remodel the TME and tumor-draining lymph nodes, depleting TREM2+ TAMs, enhancing T and natural killer (NK) cell infiltration and activation, and inducing tumor regression without systemic toxicity. This study highlights the potential for developing universal and efficacious CAR T cell therapies targeting tumor-associated macrophages for the treatment of solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ImmunologicMembrane GlycoproteinsImmunotherapy, AdoptiveTumor-Associated MacrophagesReceptors, Chimeric AntigenNeoplasmsMacrophagesAntigens, NeoplasmAnimalsHumansTumor MicroenvironmentMiceMice, TransgenicInterleukin-12T-LymphocytesCell Line, TumorKiller Cells, NaturalFemale

Stichwörter der Autor:innen

CAR-TIL-12TREM2armored CAR-Tcytokinesimmunotherapymacrophagessingle-cell sequencingsolid tumortumor-associated macrophages

Substanzen

Receptors, ImmunologicMembrane GlycoproteinsReceptors, Chimeric AntigenTREM2 protein, humanInterleukin-12Antigens, Neoplasm

Autor:innen und Institutionen

  • Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.
  • Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel. Electronic address: mvl@weizmann.ac.il.
  • Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel. Electronic address: pascale.zwicky@weizmann.ac.il.
  • Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel. Electronic address: ido.amit@weizmann.ac.il.

Förderung

  • Elsie & Marvin Dekelboum Family Foundation Rockville Inc
  • Israel Cancer Research Fund
  • Ministero della transizione ecologica
  • United States - Israel Binational Science Foundation
  • European Research Council
  • Howard Hughes Medical Institute
  • Novartis Foundation
  • Alzheimer's Association

Zitieren

APA

Yagel, G., Rimini, D., von Locquenghien, M., Avellino, R., Barboy, O., Chalan, P., Granot, G., Xie, K., Shlomi-Loubaton, S., Sheban, F., Mazuz, K., David, E., Zwicky, P., & Amit, I. (2026). Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells. Cancer Cell, 44(3), 519-533.e10. https://doi.org/10.1016/j.ccell.2025.11.009

Vancouver

Yagel G, Rimini D, von Locquenghien M, Avellino R, Barboy O, Chalan P, et al. Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells. Cancer Cell. 2026;44(3):519-533.e10. doi:10.1016/j.ccell.2025.11.009

BibTeX
@article{Yagel2026,
  author = {Yagel, Gal and Rimini, Dana and von Locquenghien, Michelle and Avellino, Roberto and Barboy, Oren and Chalan, Paulina and Granot, Gaya and Xie, Ken and Shlomi-Loubaton, Shir and Sheban, Fadi and Mazuz, Kfir and David, Eyal and Zwicky, Pascale and Amit, Ido},
  title = {Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells},
  journal = {Cancer Cell},
  year = {2026},
  volume = {44},
  number = {3},
  pages = {519--533.e10},
  doi = {10.1016/j.ccell.2025.11.009}
}
Kostenlos starten →